The Effect of Gonadotropin-Releasing Hormone Analogue on Final Adult Height in Children with Idiopathic Short Stature.


Journal

Medical principles and practice : international journal of the Kuwait University, Health Science Centre
ISSN: 1423-0151
Titre abrégé: Med Princ Pract
Pays: Switzerland
ID NLM: 8901334

Informations de publication

Date de publication:
2019
Historique:
received: 19 07 2018
accepted: 27 03 2019
pubmed: 18 4 2019
medline: 13 6 2020
entrez: 18 4 2019
Statut: ppublish

Résumé

To assess final adult height (FAH) in children with short stature treated with gonadotropin-releasing hormone analogue (GnRHa). All patients with idiopathic short stature (ISS) with normally timed puberty and a Tanner stage between 2 and 3, who achieved their FAH between 2005 and 2015, were included in this clinical historical cohort study. Height gain, FAH, and mid-parental height of 28 children with ISS who received GnRHa treatment for 1.8 ± 1.0 years to delay their puberty were compared to 31 untreated children. The FAHs of the treated and the untreated girls were 151.3 ± 5.1 and 146.8 ± 3.8 cm (p = 0.01), respectively. The FAHs of the treated and the untreated boys were 156.4 ± 4.7 and 152.3 ± 5.7 cm (p = 0.111), respectively. The height gain in the treated and the untreated girls was 1.6 ± 7.8 and -3.6 ± 5.7 cm (p = 0.036), respectively. Height gain in the treated and the untreated boys was -5.1 ± 13.6 and -11.5 ± 8.4 cm (p = 0.171), respectively. GnRHa therapy has a modest effect in improving FAH in adolescent females with ISS but not in boys.

Identifiants

pubmed: 30995651
pii: 000499929
doi: 10.1159/000499929
pmc: PMC6944933
doi:

Substances chimiques

Gonadotropin-Releasing Hormone 33515-09-2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

509-516

Informations de copyright

© 2019 The Author(s) Published by S. Karger AG, Basel.

Références

Eur J Endocrinol. 2016 Mar;174(3):R79-87
pubmed: 26466612
Eur J Pediatr. 1993 May;152(5):393-6
pubmed: 8319702
J Clin Endocrinol Metab. 1996 Sep;81(9):3318-22
pubmed: 8784090
N Engl J Med. 2003 Mar 6;348(10):908-17
pubmed: 12621135
J Clin Endocrinol Metab. 2003 Mar;88(3):1179-83
pubmed: 12629103
Best Pract Res Clin Endocrinol Metab. 2002 Sep;16(3):449-63
pubmed: 12464228
Arch Dis Child. 1970 Feb;45(239):13-23
pubmed: 5440182
PLoS One. 2016 Apr 20;11(4):e0153953
pubmed: 27097033
Pediatrics. 1998 Aug;102(2 Pt 3):507-11
pubmed: 9685454
N Engl J Med. 1998 Aug 27;339(9):599-603
pubmed: 9718379
Best Pract Res Clin Endocrinol Metab. 2015 Jun;29(3):353-66
pubmed: 26051296
J Pediatr. 1994 Jul;125(1):29-35
pubmed: 8021781
Pediatrics. 1994 Dec;94(6 Pt 1):832-40
pubmed: 7970998
J Clin Endocrinol Metab. 2008 Nov;93(11):4210-7
pubmed: 18782877
J Clin Endocrinol Metab. 1992 Feb;74(2):436-40
pubmed: 1449545
Arch Dis Child. 1969 Jun;44(235):291-303
pubmed: 5785179
Saudi Med J. 2017 Nov;38(11):1101-1107
pubmed: 29114697
Eur J Endocrinol. 2005 Feb;152(2):165-70
pubmed: 15745921
J Clin Endocrinol Metab. 2004 Jul;89(7):3138-9
pubmed: 15240583
Eur J Endocrinol. 2004 Aug;151 Suppl 1:S41-5
pubmed: 15339243
J Pediatr. 1952 Apr;40(4):423-41
pubmed: 14918032
Child Care Health Dev. 1982 Nov-Dec;8(6):327-36
pubmed: 7168886
Indian J Endocrinol Metab. 2014 Nov;18(Suppl 1):S53-62
pubmed: 25538878
J Clin Endocrinol Metab. 1993 Nov;77(5):1334-9
pubmed: 8077329
Pediatrics. 1999 Oct;104(4 Pt 2):1014-8
pubmed: 10506254
Eur J Endocrinol. 2004 Nov;151 Suppl 3:U101-8
pubmed: 15554894
Growth Horm IGF Res. 2008 Apr;18(2):111-35
pubmed: 18178498
Endocr Pract. 2015 Jun;21(6):586-9
pubmed: 25667370
Horm Res Paediatr. 2016;86(6):361-397
pubmed: 27884013

Auteurs

Nahla Khawaja (N)

The National Center (Institute) for Diabetes, Endocrinology and Genetics, University of Jordan, Amman, Jordan.

Hala Owaineh (H)

The National Center (Institute) for Diabetes, Endocrinology and Genetics, University of Jordan, Amman, Jordan.

Anwar Batieha (A)

Department of Community Medicine, Jordan University of Science and Technology, Irbid, Jordan.

Oraib Frahid (O)

The National Center (Institute) for Diabetes, Endocrinology and Genetics, University of Jordan, Amman, Jordan.

Mohammed El-Khateeb (M)

The National Center (Institute) for Diabetes, Endocrinology and Genetics, University of Jordan, Amman, Jordan.

Kamel M Ajlouni (KM)

The National Center (Institute) for Diabetes, Endocrinology and Genetics, University of Jordan, Amman, Jordan, ajlouni@ju.edu.jo.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH